The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes
| العنوان: | The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes |
|---|---|
| المؤلفون: | Xing-Chen Ding, Liang-Liang Wang, Yu-Fang Zhu, Yan-Dong Li, Shu-Lun Nie, Jia Yang, Hua Liang, Ralph R. Weichselbaum, Jin-Ming Yu, Man Hu |
| المصدر: | Frontiers in Immunology, Vol 11 (2020) Frontiers in Immunology |
| بيانات النشر: | Frontiers Media S.A., 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, 0301 basic medicine, Oncology, medicine.medical_treatment, clinical significance, medicine.disease_cause, B7-H1 Antigen, 0302 clinical medicine, glioma, Immunology and Allergy, soluble programmed cell death-ligand 1, Original Research, Mutation, biology, Brain Neoplasms, Middle Aged, Isocitrate Dehydrogenase, Gene Expression Regulation, Neoplastic, Treatment Outcome, Immunohistochemistry, Biomarker (medicine), Female, Antibody, Adult, lcsh:Immunologic diseases. Allergy, medicine.medical_specialty, Adolescent, Immunology, Programmed cell death ligand 1, Young Adult, 03 medical and health sciences, Cell Line, Tumor, Glioma, Internal medicine, mental disorders, medicine, Humans, Clinical significance, radiotherapy, Aged, business.industry, medicine.disease, Survival Analysis, Radiation therapy, 030104 developmental biology, biology.protein, prognosis, business, lcsh:RC581-607, Biomarkers, 030215 immunology |
| الوصف: | Background The programmed cell death ligand 1 (PD-L1) plays a key role in glioma development. However, due to the specificity of glioma’s anatomical position, the role of its expression as a tumor biomarker is limited. It has been proven that the levels of soluble programmed death-ligand 1 (sPD-L1) are associated with prognosis in many malignancies including glioma. However, the expression of sPD-L1 in glioma patients receiving radiotherapy (RT) remains unclear. The purpose of this study was to evaluate the concentration of sPD-L1 in the plasma of glioma patients before and after RT and to explore its relationship with clinical outcomes. Methods Between October 2017 and September 2018, glioma patients treated with RT (30 ± 10 Gy, 2 Gy/f) were enrolled, and blood samples were collected before and after RT. We quantified the sPD-L1 levels by enzyme-linked immunosorbent assay (ELISA). The isocitrate dehydrogenase-1 (IDH-1) mutational status and Ki-67 expression of tumors were evaluated by immunohistochemistry. Glioma murine model were used to address whether circulating sPD-L1 molecules are directly targeted by an anti-PD-L1 antibody. The associations between sPD-L1 and clinical features were assessed with Pearson’s or Spearman’s correlation analysis. The progression-free survival (PFS) and overall survival (OS) were determined by the Kaplan-Meier method. Results Sixty glioma patients were included, with a median age of 52 years. The proportions of grade I, II, III, and IV gliomas were 6.7%, 23.3%, 28.4%, and 41.6%, respectively. The baseline sPD-L1 levels were significantly associated with tumor grade, IDH-1 mutation status and Ki-67 expression. Using 14.35 pg/ml as the cutoff, significantly worse PFS and OS were both observed in patients with higher baseline levels of sPD-L1 (P = 0.027 and 0.008, respectively). RT significantly increased the mean level of sPD-L1 (P < 0.001). Further analysis showed that the level of sPD-L1 in IDH-1 mutation patients was higher than that in wild-type patients. Furthermore, an analysis of glioma murine model indicated that anti-PD-L1 antibody combine with RT can be a potentially powerful cancer therapy. Conclusion This study reported that sPD-L1 might be a potential biomarker to predict the outcome in glioma patients receiving RT. The elevated level of sPD-L1 after RT suggested that the strategy of a combination of immune checkpoint inhibitors and RT might be promising for glioma patients, especially for those with IDH-1 mutations. |
| اللغة: | English |
| تدمد: | 1664-3224 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d443c3d83ccaf5e058401a924e7b1b6Test https://www.frontiersin.org/articles/10.3389/fimmu.2020.580335/fullTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....1d443c3d83ccaf5e058401a924e7b1b6 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16643224 |
|---|